ABL Bio Enters Global Collaboration and License Agreement with SANOFI to Advance ABL301 for the…
ABL Bio, Inc. announced an exclusive collaboration and worldwide license agreement with SANOFI to develop and commercialize ABL301, a pre-clinical stage bispecific antibody targeting…
Read More...
Read More...
